Peter Vis

542 total citations
27 papers, 371 citations indexed

About

Peter Vis is a scholar working on Pediatrics, Perinatology and Child Health, Infectious Diseases and Virology. According to data from OpenAlex, Peter Vis has authored 27 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pediatrics, Perinatology and Child Health, 9 papers in Infectious Diseases and 7 papers in Virology. Recurrent topics in Peter Vis's work include HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Peter Vis is often cited by papers focused on HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Peter Vis collaborates with scholars based in United States, Netherlands and Belgium. Peter Vis's co-authors include Jos Delbeke, Sarah McLeay, Bruce Green, Rolf P. G. van Heeswijk, Thomas N. Kakuda, Anita Shah, Dirk Garmann, Vanitha Sekar, Meindert Danhof and Rob A. Voskuyl and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of Hepatology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Peter Vis

23 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Vis United States 12 204 87 72 70 42 27 371
Zhibin Liu China 12 86 0.4× 64 0.7× 6 0.1× 42 0.6× 7 0.2× 40 338
Lavanya Varatharajan United Kingdom 7 94 0.5× 107 1.2× 50 0.7× 18 0.3× 1 0.0× 9 288
Thomas O’Grady United States 9 80 0.4× 4 0.0× 16 0.2× 34 0.5× 3 0.1× 34 355
Jianming Xiao China 8 113 0.6× 114 1.3× 5 0.1× 32 0.5× 1 0.0× 15 337
Jennifer McCracken United States 5 46 0.2× 42 0.5× 10 0.1× 9 0.1× 3 0.1× 9 281
Mohammed I. AlJasser Saudi Arabia 10 14 0.1× 3 0.0× 23 0.3× 84 1.2× 10 0.2× 48 351
Sweta Pandey India 9 73 0.4× 2 0.0× 24 0.3× 18 0.3× 78 1.9× 18 279
Shoumik Kundu Bangladesh 10 106 0.5× 20 0.3× 25 0.4× 22 0.5× 17 302
Ekenechukwu Young Nigeria 11 21 0.1× 8 0.1× 11 0.2× 86 1.2× 1 0.0× 43 314
Nadav Sarid Israel 10 21 0.1× 15 0.2× 72 1.0× 32 0.8× 37 479

Countries citing papers authored by Peter Vis

Since Specialization
Citations

This map shows the geographic impact of Peter Vis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Vis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Vis more than expected).

Fields of papers citing papers by Peter Vis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Vis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Vis. The network helps show where Peter Vis may publish in the future.

Co-authorship network of co-authors of Peter Vis

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Vis. A scholar is included among the top collaborators of Peter Vis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Vis. Peter Vis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sutter, Gerd, et al.. (2025). Pharmacokinetics, Safety, and Dialyzability of Gadoquatrane in Patients With Impaired Renal Function. Investigative Radiology. 60(11). 779–790.
2.
Borghesi, Simone, Alessio D’Amato, Phoebe Koundouri, et al.. (2025). Reforming ESG: a European and Global South perspective. Environment and Development Economics. 30(4). 282–296.
3.
Admiraal, Marjolein M., et al.. (2023). Neuroprotection after cardiac arrest with 2-iminobiotin: a single center phase IIa study on safety, tolerability, and pharmacokinetics. Frontiers in Neurology. 14. 1136046–1136046. 1 indexed citations
4.
Goulooze, Sebastiaan C., Peter Vis, Elke H. J. Krekels, & Catherijne A. J. Knibbe. (2023). Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses. Expert Review of Clinical Pharmacology. 16(12). 1201–1209.
5.
Vis, Peter, et al.. (2020). A Phase IIa Clinical Trial of 2-Iminobiotin for the Treatment of Birth Asphyxia in DR Congo, a Low-Income Country. Pediatric Drugs. 22(1). 95–104. 8 indexed citations
6.
Peeters‐Scholte, Cacha, Anouk de Bakker, Toine C. G. Egberts, et al.. (2019). Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. Pediatric Research. 87(4). 689–696. 13 indexed citations
7.
Solms, Alexander, Alfonso Iorio, Maurice J. Ahsman, et al.. (2019). Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clinical Pharmacokinetics. 59(5). 605–616. 12 indexed citations
8.
Delbeke, Jos & Peter Vis. (2019). Towards a Climate-Neutral Europe. BiblioBoard Library Catalog (Open Research Library). 46 indexed citations
9.
Hennig, Stefanie, Elin M. Svensson, P. Bernard Fourie, et al.. (2016). Population pharmacokinetic drug–drug interaction pooled analysis of existing data for rifabutin and HIV PIs. Journal of Antimicrobial Chemotherapy. 71(5). 1330–1340. 13 indexed citations
10.
Kakuda, Thomas N., et al.. (2015). Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged≥3 to <12 Years. CPT Pharmacometrics & Systems Pharmacology. 4(7). 406–414. 10 indexed citations
11.
12.
Kakuda, Thomas N., Janet R. Wade, Eric Snoeck, et al.. (2010). Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients. Clinical Pharmacology & Therapeutics. 88(5). 695–703. 37 indexed citations
13.
Rosa, Guy De La, et al.. (2010). Pharmacokinetic (PK) and pharmacodynamic analyses of once‐ and twice‐daily darunavir/ritonavir (DRV/r) in the ODIN trial. Journal of the International AIDS Society. 13(S4). 11 indexed citations
14.
15.
Vanveggel, Simon, et al.. (2010). Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral‐naïve, HIV‐1‐infected patients in ECHO and THRIVE. Journal of the International AIDS Society. 13(S4). 19 indexed citations
16.
Blanche, Stéphane, Rosa Bologna, Pedro Cahn, et al.. (2009). Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS. 23(15). 2005–2013. 37 indexed citations
17.
Laveille, Christian & Peter Vis. (2008). Minutes from the round table held at Paris on July 6, 2007†. Fundamental and Clinical Pharmacology. 22(6). 609–612. 1 indexed citations
18.
Vis, Peter, Oscar Della Pasqua, Menno R. Kruk, et al.. (2001). Population pharmacokinetic–pharmacodynamic modelling of S 15535, a 5-HT1A receptor agonist, using a behavioural model in rats. European Journal of Pharmacology. 414(2-3). 233–243. 8 indexed citations
19.
Vis, Peter, et al.. (1994). Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat.. Journal of Pharmacology and Experimental Therapeutics. 269(2). 521–528. 23 indexed citations
20.
Vis, Peter. (1992). VAT in the Single Market: the Transitional Arrangements Explained. EC Tax Review. 1(Issue 2). 117–137. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhibin Liu Breakdown of academic impact, for papers by Lavanya Varatharajan Breakdown of academic impact, for papers by Thomas O’Grady Breakdown of academic impact, for papers by Jianming Xiao Breakdown of academic impact, for papers by Jennifer McCracken Breakdown of academic impact, for papers by Mohammed I. AlJasser Breakdown of academic impact, for papers by Sweta Pandey Breakdown of academic impact, for papers by Shoumik Kundu Breakdown of academic impact, for papers by Ekenechukwu Young Breakdown of academic impact, for papers by Nadav Sarid
Rankless by CCL
2026